Three-year PFS data from the CLL2-GIVe trial stratified by TP53 status. Patients with TP53 mutation only (n = 15, blue curve) displayed superior PFS with the triplet combination of obinutuzumab, ibrutinib, and venetoclax compared with patients with both del(17p) and TP53 mutation (biallelic TP53 loss, n = 24) or del(17p) alone (n = 2).

Three-year PFS data from the CLL2-GIVe trial stratified by TP53 status. Patients with TP53 mutation only (n = 15, blue curve) displayed superior PFS with the triplet combination of obinutuzumab, ibrutinib, and venetoclax compared with patients with both del(17p) and TP53 mutation (biallelic TP53 loss, n = 24) or del(17p) alone (n = 2).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal